Reducing Human Error In GMP Operations With Defined Work Environments

By Harry Benson

In the pharmaceutical and biotech industries, delays in getting products to market cost companies revenue and inhibit patients’ access to their medications. Those in manufacturing often seek help in closing open investigations but ignore the source of these investigations, even while the product sits quarantined. Where these firms need assistance is in reducing human error at the source.